Life
Cure8 research brief
Why This Matters
This preclinical study suggests a fox-derived Lactiplantibacillus plantarum strain can reduce inflammation and improve intestinal barrier markers in cell and mouse models of colitis, which could inform future translational work on probiotics for IBD.
Who Should Pay Attention
Researchers studying probiotics, microbiome therapeutics, and IBD pathophysiology; clinicians interested in emerging preclinical probiotic data; patients and caregivers curious about experimental probiotic research (not clinical use).
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This article reports a preclinical laboratory and animal study testing a probiotic strain (Lactiplantibacillus plantarum J3) isolated from Arctic fox intestines.
In cell culture the strain showed anti-inflammatory and antioxidant effects, and in mice given dextran sulfate sodium (DSS) to induce colitis, oral J3 reduced weight loss, lowered clinical disease scores, improved colon histology, decreased pro-inflammatory markers (TNF-α, IL-1β, IL-6, MPO, PGE2, COX-2 mRNA), and increased anti-inflammatory or barrier-related markers (IL-10, tight-junction protein mRNA, MUC2 mRNA).
The study also reports shifts in the gut microbiota and increased short-chain fatty acid levels in a subset of animals. The findings are limited to in vitro and mouse-model data and do not indicate safety or efficacy in humans.
This provides a rationale for further translational research but is not clinical evidence for use of this or any probiotic in people with IBD. If you are considering probiotics during IBD treatment, discuss this with your clinical team; animal-model results do not automatically translate to human benefit or safety.
Keep In Mind
Structured content depth: abstract — the brief is grounded in the article-provided abstract and full text; results are from cell culture and a DSS mouse model and should not be interpreted as evidence of human benefit. The study supports further research but does not change clinical practice.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationLife
PublisherMDPI AG
AuthorsYiwen Sun, Jing Lv, Xiangyu Meng +4 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 18, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: National Key R&D Program of China, award 2023YFD1302000
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Weissella confusa RY-1 ameliorates DSS-induced colitis by restoring intestinal barrier, modulating gut microbiota, and reprogramming microbial metabolism
The study shows a probiotic strain reduced inflammation and improved gut barrier and microbiome/metabolite profiles in a mouse colitis model, indicating a possible new avenue for UC therapies worth further research.
Extracellular Vesicles Derived from Elaeocarpus braceanus Alleviate DSS-Induced Ulcerative Colitis in Mice Through Multiple Pathways
This study describes a new plant-derived nanoparticle (EBDEVs) that reduced inflammation and improved colon health in a mouse model of ulcerative colitis and altered the gut microbiota — early evidence that may guide...
Extracellular vesicles from pasteurized Akkermansia muciniphila ameliorate inflammatory bowel disease through suppression of STING-driven inflammatory signaling.
This study suggests a new, non‑live (“postbiotic”) approach—extracellular vesicles from pasteurized Akkermansia muciniphila—may reduce inflammation and improve barrier function in an experimental colitis model, which...